Investigational drug · Phase 3
VVN001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dry Eye.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "VVN001"
First trial start
2024
Apr 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VVN001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dry Eye
Approved drugs for the same conditions: Dry eye disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "VVN001" as an intervention, largest first.
- Study of 5% VVN001 Ophthalmic Solution in Dry Eye DiseasePivotal-lookingRecruiting
VivaVision Biotech, IncIndustry
NCT06360133 · 700 participants (planned) · Start Apr 1, 2024 · Primary completion Apr 30, 2027
Drug: VVN001 Ophthalmic Solution, 5%; VVN001 Ophthalmic Solution, Vehicle · For: Dry Eye
Sites: Shanghai, China
- Study of VVN001 Ophthalmic Solution in Dry Eye DiseasePivotal-lookingCompleted
VivaVision Biotech, IncIndustry
NCT04556838 · 169 participants · Start Dec 3, 2020 · Primary completion Dec 1, 2021
Drug: VVN001 Ophthalmic Solution 1%; VVN001 Ophthalmic Solution 5% and 1 more · For: Dry Eye
Sites: Durham, North Carolina
Newest research
PubMed records naming it or its code names, newest first.
- A phase 2a, double-masked, randomized, vehicle-controlled trial of VVN001 in subjects with dry eye disease.
Tauber J, Evans D, Segal B, et al. · Ocul Surf 2023
- The Protective Effects of VVN001 on LPS-Induced Inflammatory Responses in Human RPE Cells and in a Mouse Model of EIU.
Qiu R, Yang M, Wang W, et al. · Inflammation 2021
Also in development for Dry Eye
- CAM-101Elate Ocular, FD hPLPhase 31 trial
Cambium Bio Limited · Dry Eye Disease, Dry Eye, Dry Eyes Chronic
- SJP-0132Phase 31 trial
Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. · Dry Eye
- 0.25% RCI001RCI001Phase 22 trials
ORA, Inc. · Dry Eye Disease (DED), Dry Eye
- TTAX03Phase 22 trials
BioTissue Holdings, Inc · Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
- BTV100Phase 21 trial
BioTheraVision, Inc. · Dry Eye
- VSJ-110Phase 21 trial
Vanda Pharmaceuticals · Dry Eye
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.